$RTGN

RetinalGenix Technologies Inc.

CIK:0001836295|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenues
Operating expenses:
General and administrative	212,254	383,729	474,403	724,932
Research and development	66,406	14,430	183,470	27,644
Stock-based compensation	24,782	250,189	234,798	482,122
Total operating expenses	303,442	648,348	892,671	1,234,698
Interest expense, net	3,955	1,070	5,215	1,979
Net loss	$ (307,397)	$ (649,418)	$ (897,886)	$ (1,236,677)
Net loss per share - basic	$ (0.02)	$ (0.03)	$ (0.05)	$ (0.07)
Net loss per share - diluted	$ (0.02)	$ (0.03)	$ (0.05)	$ (0.07)
Weighted average number of common shares outstanding during the period- basic	18,808,072	18,326,587	18,781,113	18,526,212
Weighted average number of common shares outstanding during the period- diluted	18,808,072	18,326,587	18,781,113	18,526,212

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Cash Flows From Operating Activities
Net loss	$ (307,397)	$ (590,489)	$ (649,418)	$ (587,259)	$ (897,886)	$ (1,236,677)
Non-cash items:
Stock-based compensation expense	24,782		250,189		234,798	482,122
Depreciation expense						56
Amortization of ROU asset					1,284	1,281
Expenses allocated by Sanovas on behalf of Company					330,750	330,750
Changes in operating liabilities:
Increase in accounts payable and accrued liabilities					84,198	94,602
Decrease in lease liability					(948)	(348)
Increase in accrued interest					1,920	1,920
Total adjustments					652,002	910,383
Net cash (used in) operating activities					(245,884)	(326,294)
Cash Flows From Financing Activities
Proceeds from collection of stock subscription receivable					125,000	150,000
Proceeds from sale of common stock					200,000	86,000
Advances from related parties, net					(66,658)	85,073
Net cash provided by financing activities					258,342	321,073
Net (decrease) in cash					12,458	(5,221)
Cash at beginning of period		$ 14,774		$ 6,060	14,774	6,060	$ 6,060
Cash at end of period	$ 27,232		$ 839		27,232	839	$ 14,774
Supplemental Disclosure of Cash Flow information:
Interest paid during the period
Income taxes paid during the period

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current Assets
Cash	$ 27,232	$ 14,774
Total Current Assets	27,232	14,774
Operating lease right-of-use asset	2,988	4,272
Security deposit	1,995	1,995
TOTAL ASSETS	32,215	21,041
Current Liabilities
Accounts payable and accrued liabilities	1,168,961	1,084,763
Shareholders’ notes payable	49,000	49,000
Operating lease liability – current portion	2,860	2,860
Accrued interest payable	21,199	19,279
Total Current Liabilities	2,670,178	2,319,968
Operating lease liability – long term portion	2,736	3,684
Total liabilities	2,672,914	2,323,652
Stockholder’s Deficit:
Preferred stock, $0.0001 par value; 40,000,000 shares authorized; Series F preferred stock - 3,000,000 shares designated, 0 issued and outstanding at June 30, 2026 and December 31, 2025
Common stock, $0.0001 par value; 80,000,000 shares authorized; 18,843,628 shares issued and outstanding at June 30, 2026 and December 31, 2025	1,884	1,875
Additional paid-in capital	16,113,920	15,679,131
Stock subscription receivable		(125,000)
Accumulated deficit	(18,756,503)	(17,858,617)
Total Stockholders’ Deficit	(2,640,699)	(2,302,611)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	32,215	21,041
Sanovas Ophthalmology LLC [Member]
Current Liabilities
Due to related parties	996,007	674,842
Related Party [Member]
Current Liabilities
Due to related parties	$ 432,151	$ 489,224